Treating viral hepatitis C: Efficacy, side effects, and complications

被引：506

作者：

Manns, M. P. ^{[1
]}

Wedemeyer, H. ^{[1
]}

Cornberg, M. ^{[1
]}

机构：

[1] Med Sch Hannover, Dept Gastroterol Hepatol & Endocrinol, D-30625 Hannover, Germany

来源：

GUT | 2006年 / 55卷 / 09期

关键词：

D O I：

10.1136/gut.2005.076646

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：1350 / 1359

页数：10

共 113 条

[1]

Afdhal N, 2005, J HEPATOL, V42, P39

[2] Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study [J].

Afdhal, NH ;

Dieterich, DT ;

Pockros, PJ ;

Schiff, ER ;

Shiffman, ML ;

Sulkowski, MS ;

Wright, T ;

Younossi, Z ;

Goon, BL ;

Tang, KL ;

Bowers, PJ .

GASTROENTEROLOGY, 2004, 126 (05) :1302-1311

[3] Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].

Alberti, A ;

Clumeck, N ;

Collins, S ;

Gerlich, W ;

Lundgren, J ;

Palù, G ;

Reiss, P ;

Thiebaut, R ;

Weiland, O ;

Yazdanpanah, Y ;

Zeuzem, S .

JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624

[4] Treatment of patients with hepatitis C and normal serum aminotransferase levels [J].

Bacon, BR .

HEPATOLOGY, 2002, 36 (05) :S179-S184

[5]

Bain V, 2005, J HEPATOL, V42, P9

[6] Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy [J].

Bani-Sadr, F ;

Carrat, F ;

Pol, S ;

Hor, R ;

Rosenthal, E ;

Goujard, C ;

Morand, P ;

Lunel-Fabiani, F ;

Salmon-Ceron, D ;

Piroth, L ;

Pialoux, G ;

Bentata, M ;

Cacoub, P ;

Perronne, C .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (01) :47-52

[7] The safety and efficacy of Viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naive patients infected with HCV:: Phase 3 results [J].

Benhamou, Y. ;

Pockros, P. ;

Rodriguez-Torres, M. ;

Gordon, S. ;

Shiffman, M. ;

Lurie, Y. ;

Afdhal, N. ;

Lamon, K. ;

Kim, Y. ;

Murphy, B. .

JOURNAL OF HEPATOLOGY, 2006, 44 :S273-S273

[8] What determines the natural history of recurrent hepatitis C after liver transplantation? [J].

Berenguer, M .

JOURNAL OF HEPATOLOGY, 2005, 42 (04) :448-456

[9] Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin [J].

Berg, T ;

von Wagner, M ;

Nasser, S ;

Sarrazin, C ;

Heintges, T ;

Gerlach, T ;

Buggisch, P ;

Goeser, T ;

Rasenack, J ;

Pape, GR ;

Schmidt, WE ;

Kallinowski, B ;

Klinker, H ;

Spengler, U ;

Martus, P ;

Alshuth, U ;

Zeuzem, S .

GASTROENTEROLOGY, 2006, 130 (04) :1086-1097

[10] Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: A placebo-controlled trial [J].

Berg, T ;

Kronenberger, B ;

Hinrichsen, H ;

Gerlach, T ;

Buggisch, P ;

Herrmann, E ;

Spengler, U ;

Goeser, T ;

Nasser, S ;

Wursthorn, K ;

Pape, GR ;

Hopf, U ;

Zeuzem, S .

HEPATOLOGY, 2003, 37 (06) :1359-1367

← 1 2 3 4 5 6 7 8 9 10 →